Provention Bio Inc

Provention Bio, Inc. is a clinical-stage biopharmaceutical company, which engages in the development and commercialization of novel therapeutics and solutions. Its products include PRV-031 for the interception of type 1 diabetes (T1D), PRV-015 for the treatment of gluten-free diet non-responding celiac disease, PRV-6527 for Crohn’s disease, PRV-3279 for the treatment of lupus, and PRV-101 for the prevention of acute coxsackie virus B (CVB), and the prevention of type 1 diabetes (T1D) onset. The company was founded by Francisco Leon and Ashleigh Palmer on October 4, 2016 and is headquartered in Red Bank, NJ.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Provention Bio is a clinical-stage biopharmaceutical company dedicated to sourcing, developing, and commercializing novel therapeutics and cutting-edge solutions to intercept and prevent immune-mediated disease. Their predict and prevent model is focused on developing novel therapeutic approaches that intervene before the target disease begins, re-appears, or progresses.  Provention Bio offers the potential to reduce the high morbidity, mortality, patient suffering, and escalating costs of chronic autoimmune and inflammatory diseases, such as type 1 diabetes (T1D), Crohn’s disease, ulcerative colitis, and emerging viral infections. They believe Provention’s business model, coupled with its expertise in translational medicine, immunology, and the design and execution of rapid go/no-go clinical trials, will enable them to in-license and efficiently partner both early-stage development assets and more advanced clinical-stage opportunities.

Provention Bio, Inc. (PRVB) delivered earnings and revenue surprises of 6.82% and 1.41%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?

Provention Bio, Inc. (PRVB) Reports Q4 Loss, Tops Revenue Estimates

RED BANK, N.J., Feb. 24, 2022 /PRNewswire/ -- Provention Bio, Inc. (Nasdaq: PRVB), a biopharmaceutical company dedicated to intercepting and preventing immune-mediated disease, today reported financial results for the fourth quarter and full year ended December 31, 2021, and provided a business update.

Provention Bio Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Business Update

RED BANK, N.J., Feb. 22, 2022 /PRNewswire/ -- Provention Bio, Inc. (Nasdaq: PRVB) (the "Company"), a biopharmaceutical company dedicated to intercepting and preventing immune-mediated diseases, today announced it has resubmitted the Biologics License Application (BLA) for teplizumab for the delay of clinical type 1 diabetes (T1D) in at-risk individuals.

Provention Bio Announces Biologics License Application (BLA) Resubmission for Teplizumab to Address Complete Response Letter (CRL)

RED BANK, N.J., Feb. 17, 2022 /PRNewswire/ -- Provention Bio, Inc. (Nasdaq: PRVB), a biopharmaceutical company dedicated to intercepting and preventing immune-mediated disease, today announced that it will report its fourth quarter and full year 2021 financial results on Thursday, February 24, 2022, before the opening of the U.S. financial markets.

Provention Bio to Report Fourth Quarter and Full Year 2021 Financial Results on February 24, 2022

RED BANK, N.J., Feb. 10, 2022 /PRNewswire/ -- Provention Bio, Inc. (Nasdaq: PRVB), a biopharmaceutical company dedicated to intercepting and preventing immune-mediated disease, today announced that management will participate in a fireside chat presentation at the SVB Leerink 11th Annual Global Healthcare Conference on Wednesday, February 16 th, 2022 at 10:00am EST.

Provention Bio to Present at the Virtual SVB Leerink 11th Annual Global Healthcare Conference

RED BANK, N.J., Feb. 4, 2022 /PRNewswire/ -- Provention Bio, Inc. (Nasdaq: PRVB) (the "Company"), a biopharmaceutical company dedicated to intercepting and preventing immune-mediated diseases, today announced that the Company granted stock options on February 1, 2022 to a new non-executive employee to purchase an aggregate of 30,000 shares of common stock.

Provention Bio Announces the Grant of Inducement Award

We like the risk-reward of Provention Bio at this point and upgrading the rating to strong-buy from a buy. We accumulated a small option-sized position last week to play. The company announced its intention to re-submit the BLA for Teplizumab targeting type 1 diabetes in at-risk individuals.

Provention Bio: Upgrading To A Strong-Buy, Potential Cure For Type 1 Diabetes

The momentum from the company's good news last week is continuing this week.

Why Provention Bio Stock Skyrocketed Today

The company plans to refile for approval of its experimental type 1 diabetes therapy.

Why Provention Bio Stock Is Soaring Today

Enservco

Inspira Technologies Oxy BHN Ltd

Mind Medicine MindMed

Penny stocks to buy for under $5. The post 5 Top Penny Stocks To Buy Under $5 Right Now appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

5 Top Penny Stocks To Buy Under $5 Right Now

RED BANK, N.J., Jan. 27, 2022 /PRNewswire/ -- Provention Bio, Inc. (Nasdaq: PRVB) (the "Company"), a biopharmaceutical company dedicated to intercepting and preventing immune-mediated diseases, today announced its intent to resubmit the teplizumab Biologics License Application (BLA) for the delay of clinical type 1 diabetes in at-risk individuals following its Type B pre-BLA resubmission meeting with the U.S. Food and Drug Administration (FDA).

Provention Bio Resubmitting Biologics License Application for Delay of Clinical Type 1 Diabetes in At-Risk Individuals Following Type B Meeting with the FDA

Provention Bio Inc (NASDAQ: PRVB) has initiated the Phase 2a PREVAIL-2 study evaluating PRV-3279 in systemic lupus erythematosus (SLE). PRV-3279 is a humanized bispecific DART molecule targeting the B-cell surface proteins CD32B & CD79B, which can intercept the pathophysiology of SLE & other B cell-mediated autoimmune diseases and prevent the immunogenicity of gene therapies.

Provention Bio Starts Mid-Stage Lupus Trial; Data Expected In 2024

RED BANK, N.J., Jan. 20, 2022 /PRNewswire/ -- Provention Bio, Inc. (Nasdaq: PRVB), a biopharmaceutical company dedicated to intercepting and preventing immune-mediated disease, today announced the initiation of the Phase 2a PREVAIL-2 study (PRV-3279 EVAluation In Lupus- Phase 2).

Provention Bio Announces Initiation of the Phase 2a PREVAIL-2 Study of PRV-3279 (CD32B × CD79 Bispecific DART® Molecule) in Systemic Lupus Erythematosus (SLE)

RED BANK, N.J., Jan. 6, 2022 /PRNewswire/ -- Provention Bio, Inc. (Nasdaq: PRVB), a biopharmaceutical company dedicated to intercepting and preventing immune-mediated disease, today announced that management will present at the H.C.

Provention Bio to Present at the Virtual H.C. Wainwright BioConnect Conference

RED BANK, N.J. , Dec. 20, 2021 /PRNewswire/ -- December 20, 2021— Provention Bio, Inc. (NASDAQ: PRVB) (the "Company"), a biopharmaceutical company dedicated to intercepting and preventing immune-mediated diseases, today announced that the Company has appointed Christina Yi as Chief Operations Officer, responsible for manufacturing, supply chain and human resources, and Benedict Osorio as Chief Quality Officer, responsible for all aspects of quality.

Provention Bio Announces Leadership Team Expansion

The consensus price target hints at a 167.3% upside potential for Provention Bio, Inc. (PRVB). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.

Wall Street Analysts Predict a 167% Upside in Provention Bio, Inc. (PRVB): Here's What You Should Know

The stock price of Provention Bio Inc (NASDAQ: PRVB) increased by 15.06% in the most recent trading session. This is why it happened.

Provention Bio (PRVB) Stock: Why The Price Jumped

The FDA has approved Provention Bio Inc's (NASDAQ: PRVB) proceeding to populate the popPK model with data collected from patients receiving therapeutic doses of teplizumab PK/PD substudy. Related Link:   Provention Bio's Teplizumab Application Receives CRL For Type-1 Diabetes; Stock Drops

Provention Bio Shares Gain On Teplizumab Regulatory Update For Type 1 Diabetes

RED BANK, N.J., Nov. 22, 2021 /PRNewswire/ -- Provention Bio, Inc. (Nasdaq: PRVB), a biopharmaceutical company dedicated to intercepting and preventing immune-mediated disease, today provided an update on its ongoing efforts to address U.S. Food and Drug Administration (FDA) considerations cited in the Complete Response Letter (CRL) issued to the Company by the FDA on July 2, 2021, pertaining to comparability between the Company's planned teplizumab commercial product and clinical drug product used in historical trials of teplizumab.

Provention Bio Provides Regulatory Update for Teplizumab At-Risk Type 1 Diabetes Approval Pathway

RED BANK, N.J., Nov. 17, 2021 /PRNewswire/ -- Provention Bio, Inc. (Nasdaq: PRVB), a biopharmaceutical company dedicated to intercepting and preventing immune-mediated disease, today announced the appointment of Jan Hillson, M.D.

Provention Bio Appoints Jan Hillson, M.D., as Senior Vice President of Clinical Development

Provention Bio, Inc. (PRVB) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Provention Bio, Inc. (PRVB) Upgraded to Buy: What Does It Mean for the Stock?

The average of price targets set by Wall Street analysts indicates a potential upside of 187.1% in Provention Bio, Inc. (PRVB). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.

How Much Upside is Left in Provention Bio, Inc. (PRVB)? Wall Street Analysts Think 187%

RED BANK, N.J., Nov. 9, 2021 /PRNewswire/ -- Provention Bio, Inc. (Nasdaq: PRVB), a biopharmaceutical company dedicated to intercepting and preventing immune-mediated disease, today announced it's putting type 1 diabetes (T1D) to the test during Diabetes Awareness Month this November.

Provention Bio Puts Type 1 Diabetes to the Test with Pledge Campaign for Diabetes Awareness Month

RED BANK, N.J., Nov. 5, 2021 /PRNewswire/ -- Provention Bio, Inc. (Nasdaq: PRVB), a biopharmaceutical company dedicated to intercepting and preventing immune-mediated disease, today announced the appointment of Miguel Sanjuan, Ph.D.

Provention Bio Appoints Miguel Sanjuan, Ph.D. as Senior Vice President of Research and Early Development

Provention Bio, Inc. (PRVB) CEO Ashleigh Palmer on Q3 2021 Results - Earnings Call Transcript

News for Provention Bio Inc Stock (PRVB)